Recently, Shi Yuanyuan, Chairman and General Manager of Shenzhen Cell Valley Group, led a delegation including Han Han (Head of Shandong Region), Zhu Wenxiang (Senior R&D Scientist), Sun Rui (Head of Business Development), and Wu Hua (Project Manager) on a visit to Yantai Yuhuangding Hospital. They were invited to hold symposiums and exchanges with Song Xicheng (Secretary of the Party Committee and President of Yantai Yuhuangding Hospital), Vice Presidents Sun Chengming, Sun Ping, Wu Jitao, Qiao Guangdong, and relevant department heads and key personnel. The discussions focused on comprehensive and in-depth research regarding cooperation directions and implementation paths in the field of cell therapy.

At the exchange meeting, Hospital President Song Xicheng provided a comprehensive introduction to the hospital's discipline construction, research strength, and achievements in clinical translation. As a regional medical benchmark, the hospital has cultivated the field of cell therapy for many years, establishing an international-standard platform for clinical research and translation and assembling a multidisciplinary professional team. Its stem cell clinical research projects have achieved the best provincial uation results, and multiple research achievements have been translated into clinical applications, accumulating rich experience in cell therapy clinical exploration for difficult diseases such as tumors, blood system disorders, and rare diseases.

Chairman Shi Yuanyuan expressed recognition of Yantai Yuhuangding Hospital's "hardcore" strength and fruitful results in the field of cell therapy clinical research. He shared Shenzhen Cell Valley's core layout and industrial advantages in the cell and gene therapy sector. As the only enterprise in Asia possessing a GMP industrial production platform for clinical-grade retroviral vectors, Shenzhen Cell Valley has deeply cultivated the cell and gene therapy track. Backed by dual support from government special funds and social capital, the company has built over 10,000 square meters of standardized production, quality control, and R&D facilities. Its viral vector and cell products have gained recognition from the CDE and FDA, possessing one-stop service capabilities from R&D to industrial implementation, providing full-chain technical support for clinical translation.

During the core exchange session, combining clinical diagnosis and treatment needs with frontier technology R&D directions, the two sides focused on the clinical application of NK cell and CAR-T cell therapies. In-depth discussions were held on key topics including cell therapy regimens for advanced solid tumors, hematologic malignancies, urological tumors, and breast cancer, as well as the treatment of osteoarthritis using mesenchymal stem cells/exosomes and the subsequent translation of completed stem cell clinical research projects. Both sides fully exchanged technical ideas and cooperation concepts, reaching a high degree of consensus on multiple cooperation directions and clarifying the core focal points for subsequent joint R&D and clinical translation.

This collaboration between the medical institution and the enterprise coincides with the policy window of the imminent formal implementation of the "Regulations on the Administration of Clinical Research and Clinical Translation Application of Biomedical New Technologies" (referred to as the "818 Regulations"). The standardized guidance of the policy lays a solid foundation for the high-quality development of cell therapy technology. Leveraging Shenzhen Cell Valley's industrial advantages in technology R&D and industrial implementation, combined with Yantai Yuhuangding Hospital's clinical resources, case accumulation, and diagnostic experience, the two parties will achieve precise docking of medical-enterprise resources and complementary advantages. This will clear the critical path of "Technology R&D - Clinical Validation - Achievement Translation," promoting cell therapy technology from the laboratory to the clinic to effectively benefit patients with difficult-to-treat diseases.

In the future, both parties will take this seminar as the starting point for cooperation, establishing a long-term communication and cooperation mechanism. They will conduct in-depth cooperation in cell therapy clinical research, technology translation, and project implementation, jointly tackling frontier medical challenges, accelerating the clinical translation and large-scale application of cell and gene therapy technologies, empowering precision medicine development with technological innovation, and contributing a combined medical-enterprise force to the upgrading of China's biopharmaceutical industry and the protection of people's health.

About Yantai Yuhuangding Hospital

Yantai Yuhuangding Hospital is a Grade A tertiary general hospital and a regional medical center in Shandong Province, ranking among the top prefecture-level hospitals in China for comprehensive strength. As a national filing base for stem cell clinical research, the hospital has deeply cultivated the frontier field of cell therapy, establishing an international-standard platform for clinical research and translation and assembling a multidisciplinary professional team with outstanding strength in research and clinical translation. In the uation of stem cell clinical research projects by the National Health Commission, the hospital's two filed projects were both rated Grade B, the best in the province. Notably, the world's first human umbilical cord mesenchymal stem cell injection project for the treatment of moderate-to-severe persistent allergic rhinitis has already been translated and implemented in Beidaihe.